File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.23876/j.krcp.21.285
- Scopus: eid_2-s2.0-85142845876
- WOS: WOS:000933585900006
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors
Title | Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors |
---|---|
Authors | |
Keywords | Diabetic kidney disease Diabetic nephropathies Glucagon-like peptide-1 receptor agonist Non-steroidal mineralocorti-coid receptor antagonist Selective endothelin receptor antagonist Sodium-glucose transporter 2 inhibitors |
Issue Date | 1-Nov-2022 |
Publisher | The Korean Society of Nephrology |
Citation | Kidney Research and Clinical Practice, 2022, v. 41, n. 6, p. 682-698 How to Cite? |
Abstract | Progress in the treatment of diabetic kidney disease (DKD) has been modest since the early trials on renin-angiotensin-aldosterone system inhibitors (RAASis). Although sodium-glucose co-transporter 2 inhibitors (SGLT2is) have revolutionized the management of DKD by lowering proteinuria and protecting organs, other novel treatment approaches with good evidence and efficacy that can be used in conjunction with a RAASi or SGLT2i in managing DKD have emerged in the past few years. This review discusses the evidence for glucagon-like peptide-1 receptor agonist, selective mineralocorticoid receptor antagonist, and selective endothelin A receptor antagonist, emerging treatment options for DKD beyond SGLT2 inhibition. |
Persistent Identifier | http://hdl.handle.net/10722/338815 |
ISSN | 2023 Impact Factor: 2.9 2023 SCImago Journal Rankings: 0.820 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chan, Anthony T P | - |
dc.contributor.author | Tang, Sydney C W | - |
dc.date.accessioned | 2024-03-11T10:31:45Z | - |
dc.date.available | 2024-03-11T10:31:45Z | - |
dc.date.issued | 2022-11-01 | - |
dc.identifier.citation | Kidney Research and Clinical Practice, 2022, v. 41, n. 6, p. 682-698 | - |
dc.identifier.issn | 2211-9132 | - |
dc.identifier.uri | http://hdl.handle.net/10722/338815 | - |
dc.description.abstract | Progress in the treatment of diabetic kidney disease (DKD) has been modest since the early trials on renin-angiotensin-aldosterone system inhibitors (RAASis). Although sodium-glucose co-transporter 2 inhibitors (SGLT2is) have revolutionized the management of DKD by lowering proteinuria and protecting organs, other novel treatment approaches with good evidence and efficacy that can be used in conjunction with a RAASi or SGLT2i in managing DKD have emerged in the past few years. This review discusses the evidence for glucagon-like peptide-1 receptor agonist, selective mineralocorticoid receptor antagonist, and selective endothelin A receptor antagonist, emerging treatment options for DKD beyond SGLT2 inhibition. | - |
dc.language | eng | - |
dc.publisher | The Korean Society of Nephrology | - |
dc.relation.ispartof | Kidney Research and Clinical Practice | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | Diabetic kidney disease | - |
dc.subject | Diabetic nephropathies | - |
dc.subject | Glucagon-like peptide-1 receptor agonist | - |
dc.subject | Non-steroidal mineralocorti-coid receptor antagonist | - |
dc.subject | Selective endothelin receptor antagonist | - |
dc.subject | Sodium-glucose transporter 2 inhibitors | - |
dc.title | Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors | - |
dc.type | Article | - |
dc.identifier.doi | 10.23876/j.krcp.21.285 | - |
dc.identifier.scopus | eid_2-s2.0-85142845876 | - |
dc.identifier.volume | 41 | - |
dc.identifier.issue | 6 | - |
dc.identifier.spage | 682 | - |
dc.identifier.epage | 698 | - |
dc.identifier.eissn | 2211-9140 | - |
dc.identifier.isi | WOS:000933585900006 | - |
dc.identifier.issnl | 2211-9132 | - |